ADMS News
Archived Headlines
- Adamas Pharmaceuticals prices IPO at $16, the low end of the range 04/09/14
- 16 US IPOs planned for the week of Apr 7 04/07/14
- CNS disorders pharmaceutical Adamas Pharmaceuticals sets terms for $51 million IPO 03/26/14
- US IPO Recap: Coupons.com jumps 88% and Biomet files for an IPO 03/10/14
- CNS disorders pharmaceutical Adamas files for a $69 million IPO 03/05/14
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals sets terms for $60 million IPO
Vitae Pharmaceuticals, which uses software to develop small molecule drugs for type 2 diabetes and Alzheimer's, announced terms for its IPO on Monday. The Fort Washington, PA-based company plans to raise $60 million by offering 5.0 million shares at a price...read more
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals files for a $55 million IPO
Vitae Pharmaceuticals, which is using advanced software to design drugs for type 2 diabetes and Alzheimer's, filed on Tuesday with the SEC to raise up to $55 million in an initial public offering. The company claims its drug delivery platform, Countour, uses...read more
Seizure biotech Sage Therapeutics sets terms for $60 million IPO
Sage Therapeutics, a biotech developing treatments for life-threatening seizures, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 to $16. At the midpoint of...read more
Schizophrenia biotech Minerva Neurosciences files for a $69 million IPO
Minerva Neurosciences, a clinical stage biotech developing treatments for CNS diseases, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company has four candidates designed to treat schizophrenia, major depressive...read more